Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with ...

CAMBRIDGE & LEXINGTON, Mass.--(BUSINESS WIRE)--Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc.

(RTTNews) - Korro Bio, Inc., an RNA editing firm, and Frequency Therapeutics, Inc. (FREQ), announced on Friday that they have signed a deal to combine the two firms in an all-stock transaction. The ...

Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fund operations into 2026 Funds multiple potentially ...

Korro will be focused on advancing a wholly owned portfolio of RNA editing programs Post-transaction cash of approximately $170 million expected to fund operations into 2026 Funds multiple potentially ...

Venture-backed Korro Bio of Cambridge said Friday it will absorb financially struggling Frequency Therapeutics through a reverse merger in which Korro will take over Frequency’s public stock listing ...